Skip to search formSkip to main contentSkip to account menu

Enbrel

Known as: enbrel [brand name] 
brand name of a drug that is used to treat rheumatism
National Institutes of Health

Related topics

Related topics

4 relations
0.51 ML Etanercept 50 MG/ML Prefilled Syringe [Enbrel]0.98 ML Etanercept 50 MG/ML Auto-Injector [Enbrel]Diastat

Broader (1)

Etanercept

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Complete mapping of disulfide linkages for etanercept products by multi-enzyme digestion coupled with LC-MS/MS using multi-fragmentations including CID and ETD
2018
2018
Glycosimilarity assessment of biotherapeutics 1: Quantitative comparison of the N‐glycosylation of the innovator and a biosimilar version of etanercept
2018
2018
Simple and Robust N-Glycan Analysis Based on Improved 2-Aminobenzoic Acid Labeling for Recombinant Therapeutic Glycoproteins.
2018
2018
Tumor necrosis factor‐α mediated pain hypersensitivity through Ret receptor in resiniferatoxin neuropathy
2008
2008
Weighing benefits and risks
Although drugs that act to suppress part of the immune system are invaluable in the treatment of certain autoimmune disorders… 
Review
2004
Review
2004
Etanercept (Enbrel) -- an update.
Etanercept is a tumor necrosis factor antagonist with anti-inflammatory effects. It is currently approved in the US for psoriasis… 
Review
2003
Review
2003
Biologic therapies in the spondyloarthritis: new opportunities, new challenges
Therapeutic options for patients suffering from the more severe forms of spondyloarthritis have been rather limited in the last… 
2002
2002
Short Communication: Effect of Etanercept (Enbrel) on Interleukin 6, Tumor Necrosis Factor α, and Markers of Immune Activation in HIV-Infected Subjects Receiving Interleukin 2
The effect of etanercept, a soluble p75 tumor necrosis factor (TNF) receptor:Fc fusion protein (Enbrel; Immunex, Seattle, WA) on… 
2002
2002
Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2.
The effect of etanercept, a soluble p75 tumor necrosis factor (TNF) receptor:Fc fusion protein (Enbrel; Immunex, Seattle, WA) on… 
2001
2001
Reducing mortality associated with immediate treatment complications of adult leukemias.
  • E. Estey
  • Seminars in hematology (Print)
  • 2001
  • Corpus ID: 34052544
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)